Ronald Devine, MD
Infectious Disease · Atlanta, GANPI 1174637532
Payments from drug & device makers
Across 93 payments — averaging $39.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$2K
- AbbVie$525
- Astellas Pharma US Inc$288
- Merck$245
- Viiv Healthcare Company$120
- Melinta Therapeutics, LLC$103
- plus $476 from 14 others
What the payments were for
- Speaking & faculty fees$1,63945%
- Travel & lodging$180%
- Food & beverage$1,91153%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 7 | $1,872 |
| AbbVie(2 entities) | 32 | $525 |
| Astellas Pharma US Inc | 11 | $288 |
| Merck | 11 | $245 |
| Viiv Healthcare Company | 5 | $120 |
| Melinta Therapeutics, LLC | 4 | $103 |
| La Jolla Pharmaceutical Company | 4 | $79 |
| Cumberland Pharmaceuticals, Inc. | 2 | $59 |
| Insmed, Inc. | 2 | $50 |
| Aimmune Therapeutics, Inc. | 2 | $49 |
| Gilead | 2 | $47 |
| Napo Pharmaceuticals Inc | 2 | $38 |
| Mayne Pharma Commercial LLC | 2 | $30 |
| Shionogi Inc | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $20 |
| Theratechnologies Inc. | 1 | $20 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Hydrofera LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$1,772
How this compares
$3,629 in reported general payments places this provider in the 60th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 40 | $27,737 |
| Cefazolin Sodium | 27 | $1,546 |
| Cefadroxil | 30 | $1,132 |
| Doxycycline Hyclate | 15 | $669 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $608 |
| CeftriaxoneCeftriaxone Sodium | 12 | $574 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $195 |
| Ciprofloxacin Hcl | 13 | $124 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Atlanta
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Zandraetta Tims-CookAtlanta$878K
- Scott FridkinAtlanta$774K
- Colleen KelleyAtlanta$738K
- Leandro MenaAtlanta$733K
- Srilatha EdupugantiAtlanta$726K
- Larry AndersonAtlanta$694K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.